The last time I wrote about REGENXBIO Inc. (RGNX) it was in a Seeking Alpha article entitled "Regenxbio: DMD Program Lends Additional Credibility to NAV Technology platform." At the time, I spoke ...
ROCKVILLE, Md., Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II ...
ROCKVILLE, Md., Feb. 8, 2021 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that additional positive interim data from a total of eight patients in Cohorts 1 and 2 of the ongoing Phase I ...
ROCKVILLE, Md., Feb. 22, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive interim data from the Phase I/II/III CAMPSIITE™ trial of RGX-121 for the treatment of ...
REGENXBIO specializes in gene therapies using proven AAV technology. RGX-121, targets Hunter syndrome and is under FDA review, with a PDUFA date set for November 9, 2025. We believe the upcoming FDA ...
Last Wednesday, REGENXBIO Inc (NASDAQ:RGNX) reported additional interim safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne muscular dystrophy ages 4 to11 ...
(RTTNews) - REGENXBIO Inc. (RGNX) Tuesday said that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RGX-121 for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results